Blog

Rasika Bombatkar: The rejection of my application for adjuvant Osimertinib is disheartening to say the least

Photo of Rasika Bombatkar from gtc.ox.ac.uk

Feb 23, 2024, 14:31

Rasika Bombatkar: The rejection of my application for adjuvant Osimertinib is disheartening to say the least

Rasika Bombatkar, Citizen Scientist at LUNGevity Foundation, cancer patient and advocate, shared on X:

“AstraZeneca, your commitment to helping people access vital medicines is crucial and expected. However, the rejection of my application for adjuvant Osimertinib is disheartening to say the least.

Reply from your medical team states there is “no data on clinical benefits” with Osimertinib for someone like me with a stage III lung cancer with EGFR exon 19 deletion post surgery. Denying access to a proven lifesaver raises questions about the value placed on lives like mine.

Let’s ensure equitable access for all patients in need.”

Source: Rasika Bombatkar/X

access to treatment adjuvant EGFR inhibitor AstraZeneca cancer cancer patient EGFR exon 19 deletion Lung cancer OncoDaily Oncology osimertinib Rasika Bombatkar

New Paper Alert! HR+ Breast Cancer: Efficacy of Subsequent Treatments After CDK4/6 Inhibitor Progression

Carlos Rodriguez-Galindo: The Man Who Will Cure the World

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

Special Coverage